New class of drugs for treatment of severe inflammatory conditions and resistant cancer
The fractalkine axis controls pro-inflammatory cells and cancer cells with precision
"Having three clinical studies in the pipeline, all with potential to address medical needs in diseases with significant market opportunities, I feel very confident about Kancera’s opportunities."
Peter Selin, CEO Kancera
2023-11-17Kancera provides operational update in connection with release of financial interim report for third quarter 2023
2023-11-17Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851
2023-10-23Kancera reports that the phase I study of KAND145 has received regulatory approval